| Literature DB >> 27608012 |
Xue-Bin Ling1, Hong-Wei Wei2, Jun Wang3, Yue-Qiong Kong4, Yu-You Wu5, Jun-Li Guo6, Tian-Fa Li7, Ji-Ke Li8.
Abstract
Mammalian metallothionein-2A (MT2A) has received considerable attention in recent years due to its crucial pathophysiological role in anti-oxidant, anti-apoptosis, detoxification and anti-inflammation. For many years, most studies evaluating the effects of MT2A have focused on reactive oxygen species (ROS), as second messengers that lead to oxidative stress injury of cells and tissues. Recent studies have highlighted that oxidative stress could activate mitogen-activated protein kinases (MAPKs), and MT2A, as a mediator of MAPKs, to regulate the pathogenesis of various diseases. However, the molecule mechanism of MT2A remains elusive. A deeper understanding of the functional, biochemical and molecular characteristics of MT2A would be identified, in order to bring new opportunities for oxidative stress therapy.Entities:
Keywords: metallothionein-2A; mitogen-activated protein kinases; oxidative stress; reactive oxygen species
Mesh:
Substances:
Year: 2016 PMID: 27608012 PMCID: PMC5037761 DOI: 10.3390/ijms17091483
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Structure of human metallothionein-2 (MT-2). Amino acid sequence and 3D structure were retrieved from UniProt (P02795). Class I MT2 contains 2 metal-binding domains: four divalent ions are chelated within cluster A of the α-domain and are coordinated via cysteinyl thiolate bridges to 11 cysteine ligands. Cluster B, the corresponding region within the β-domain, can ligate three divalent ions to 9 cysteines. The 3D structures show that cluster A could bind three metal ions (Cd2+), and cluster B could bind four metal ions (Cd2+), respectively.
Figure 2Interactions of subcellular structure during oxidative stress and activation cell apoptosis pathway through mitogen-activated protein kinases (MAPKs). Mammalian metallothionein-2A (MT2A) might inhibit oxidative stress through four subcellular structures. Mitochondrial Stress—MS, Endoplasmic Reticulum Stress—ERS, Lysosomal Membrane Permeabilization Stress—LMPS, Lipid Peroxidation Injury—LPI, Endothelial Nitric Oxide Synthase—eNOS: (green arrows: caused definitely, brown dotted arrows: caused indefinitely, Inhibit(−)).
Figure 3MAPKs pathway during oxidative stress. MAPKs pathway is typically initiated by G protein–coupled receptor or by stress stimuli, then triggers a cascade of phosphorylation reactions, and finally leads to various cell biological effects. MT2A might inhabit MAPKs in oxidative stress. (blue arrows: caused definitely, brown dotted arrows: caused indefinitely, Inhibit(−).)
Summary of MT2A in relation to disease.
| Reference | Tissue Type/Sample Size | Findings |
|---|---|---|
| Chung, et al. [ | Rat: cortical neuron cells;treated with/without Aβ1–40; | MT-2A was capable of therapeutic approach to AD |
| Yang, et al. [ | Human: Peripheral blood; 287CHD; 226 control | The gene polymorphism of MT2A-838G/C was correlated to CHD |
| Xu, et al. [ | Mice: myocytes; 6 wild-type; 6 cardiac-specific MT transgenic mice; Rats: H9c2 and H9c2MT7 cells; | MT2A could prevent diabetes-induced cardiac ERS, which contributed to prevent DCM |
| Xue, et al. [ | Rats: H9c2 and H9c2MT7 cells; | MT2A markedly increased oxidative protection induced by H/R or Cd toxicity in rat cardiac myocytes |
| Jakovac, et al. [ | Rats: Tissues: spinal cord, liver; BBH and DA | MT2A had neuroprotective role of autoimmune encephalomyelitis |
| Miyazaki, et al. [ | Mice: Tissues: astrocytes, the striatum; 6-hydroxydopamine-Lesioned parkinsonian model mice; control; | MT2A provided a promising therapeutic strategy in Parkinson’s disease |
| Pan, et al. [ | Human: Gastric tumor tissue; 684 GCs patients cohort; 258 GC patients subset | MT2A might be a chemosensitivity indicator in GC patients |
| Kayaalti, et al. [ | Human: Peripheral blood; 354 individuals aged between 18 and 95 | The IL-6-174C+ carriers and MT2A-5 G-carriers might be more advantageous for longevity |
| Giacconi, et al. [ | Human: Peripheral blood; 91 Type 2 diabetes patients; 188 control | The MT2A polymorphism was associated with Type 2 diabetes and atherosclerosis |
| Nakazato, et al. [ | Human: Peripheral blood; 18 chronic hepatitis C patients and 19 Wilson’s disease patients; 200 control | A significantly elevated MT2A was found in patients with chronic hepatitis and Wilson’s disease |
| Xu, et al. [ | Human: LX-2 cell from human hepatic stellate; pEGFP-N1-hMT-IIA and pEGFP-N1 were transfected into LX-2 cells; | Liver fibrosis might be treated by MT2A |
MT7: human MT-IIA over-expressing cardiac cell line; BBH: bovine brain homogenate rats; DA: Dark Agouti rats; IID: itai-itai disease; DCM: dilated cardiomyopathy.